EVOGEN, INC.
Lenexa, KS · CIK 0001170875 · Medtech · Private
Blood test that differentiates psychogenic non-epileptic seizures (PNES) from epilepsy
evogen.com →- Grants
- $842K
- 3 awards
- Sector median: 1
- Raised
- $1.9M
- 2 Form D · Feb 2014
- 152 months since last filing
- Contracts
- $841K
- 4 awards · the Interior, Defense
- #340 of 4531 in medtech
- Patents
- 8
- 3 granted · 5 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2008201020122014201620182020
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal contract | Department of the Interior · Air Sampler | $11,379 | |
| Federal contract | Department of Defense · Evaluation Of Units | $3,400 | |
| Private capital raised | Form D · SEC | $1,041,322 | |
| Federal contract | Department of Defense · SBIR Phase I (A103-154-0413) | $789,500 | |
| Federal contract | Department of Defense · Ram 31 High Production Dry Stripping Cab | $36,406 | |
| Private capital raised | Form D · SEC | $852,420 | |
| Federal grant | Department of Health and Human Services · Phase I · Diagnostic Test for Detecting Recent Seizures in Epilepsy Patients | $224,515 | |
| Federal grant | Department of Health and Human Services · Phase I · Assessment of Peripherally Circulating Plasma Proteins and Clinical Risks to Differentiate Epileptic Seizure from Psychogenic Nonepileptic Seizure | $562,119 | |
| Federal grant | Department of Health and Human Services · Phase I · Assessment of Peripherally Circulating Plasma Proteins and Clinical Risks toDifferentiate Epileptic Seizure from Psychogenic Nonepileptic Seizure | $55,000 |
Federal grant · SBIR/STTRFederal contract · USAspendingForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 337 | MICHIGAN CRITICAL CARE CONSULTANTS, INC. | $849K | $34M |
| 338 | MEMSEL INC. | $844K | — |
| 339 | EASEALERT LLC | $842K | $200K |
| 340 | EVOGEN, INC. | $841K | $1.9M |
| 341 | BOOST TREADMILLS LLC | $807K | — |
| 342 | Ninepoint Medical, Inc. | $783K | $70M |
| 343 | GRADIENT HEALTH, INC. | $766K | $7.9M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Robert DondesExecutive Officer
- Thomas JantschDirector · Executive Officer
- Hans KastensmithDirector · Executive Officer · Promoter
- Nathan LedeboerDirector
- Jonathan LeitersdorfDirector
- John LevyDirector
- Sean ReinekeDirector
- James SpigarelliDirector
- Richard St. ClairExecutive Officer
Patents
- Biomarkers And Methods For Detection Of Seizures And Epilepsygranted
- Biomarkers And Methods For Detection Of Seizures And Epilepsygranted
- Biomarkers And Methods For Detection Of Seizures And Epilepsygranted
- Biomarkers And Methods For Detection Of Seizures And Epilepsyapplication
- Biomarkers And Methods For Evaluation And Treatment Of Epileptic Vs Non-epileptic Seizures / No Seizures / Psychogenic Non-epileptic Seizuresapplication
- Biomarkers And Methods For Detection Of Seizures And Epilepsyapplication
- Biomarkers And Methods For Detection Of Seizures And Epilepsyapplication
- Methods Of Quantifying Nucleic Acidsapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.